InvestorSoup.com issues Technical Trading Outlook for Facet Biotech Corp.
The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, September 14, 2009 ) DALLAS, Texas - InvestorSoup.com announces an investment report featuring Facet Biotech Corp. (Nasdaq: FACT).
The investment report for Facet Biotech Corp. (Nasdaq: FACT) will be of particular interest to other biotechnology companies: Biogen Idec Inc. (Nasdaq: BIIB), Trubion Pharmaceuticals Inc. (Nasdaq: TRBN), Roche Holding Ltd. (OTC PK: RHHBY) and Seattle Genetics Inc. (Nasdaq: SGEN).
It is available at: http://www.investorsoup.com/lp/FACT
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Facet Biotech Corp. (Nasdaq: FACT) is a biotechnology company that identifies and develops oncology therapeutics. The Company has four clinical stage monoclonal antibodies: Daclizumab, Volociximab, Elotuzumab, and PDL192. In addition to developing its clinical-stage products, the Company focuses on leveraging its research and development capabilities to identify and develop new oncology drugs and applying its proprietary next-generation protein engineering technologies to improve the clinical performance of protein therapeutics.
In the report, the analyst notes:
“On September 8, 2009, FACT rejected an unsolicited takeover bid from BIIB for $356 million stating that the offer was ‘inadequate.’ BIIB offered to pay the Company $14.50 a share on September 4, 2009, a 64% premium over the market price. The Company said that the offer only represented cash on its balance sheet and did not attribute any value to Daclizumab or to the rest of the Company’s existing R&D pipeline and platform. The decision to reject the bid caused FACT’s share price to rise 11%, which could suggest that investors expect a higher offer in the future.
“BIIB initially offered FACT $15 a share on August 21, 2009, which FACT rejected on August 25, 2009. On August 28, 2009, FACT announced that it signed a $186.5 million in-licensing deal with Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) for TRU-016, a phase I drug for chronic lymphocytic leukemia (CLL). BIIB said the agreement reduces the value of FACT and noted that FACT’s share prices fell substantially after the announcement of the collaboration.”
To read the entire report visit: http://www.investorsoup.com/lp/FACT
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.
The investment report for Facet Biotech Corp. (Nasdaq: FACT) will be of particular interest to other biotechnology companies: Biogen Idec Inc. (Nasdaq: BIIB), Trubion Pharmaceuticals Inc. (Nasdaq: TRBN), Roche Holding Ltd. (OTC PK: RHHBY) and Seattle Genetics Inc. (Nasdaq: SGEN).
It is available at: http://www.investorsoup.com/lp/FACT
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Facet Biotech Corp. (Nasdaq: FACT) is a biotechnology company that identifies and develops oncology therapeutics. The Company has four clinical stage monoclonal antibodies: Daclizumab, Volociximab, Elotuzumab, and PDL192. In addition to developing its clinical-stage products, the Company focuses on leveraging its research and development capabilities to identify and develop new oncology drugs and applying its proprietary next-generation protein engineering technologies to improve the clinical performance of protein therapeutics.
In the report, the analyst notes:
“On September 8, 2009, FACT rejected an unsolicited takeover bid from BIIB for $356 million stating that the offer was ‘inadequate.’ BIIB offered to pay the Company $14.50 a share on September 4, 2009, a 64% premium over the market price. The Company said that the offer only represented cash on its balance sheet and did not attribute any value to Daclizumab or to the rest of the Company’s existing R&D pipeline and platform. The decision to reject the bid caused FACT’s share price to rise 11%, which could suggest that investors expect a higher offer in the future.
“BIIB initially offered FACT $15 a share on August 21, 2009, which FACT rejected on August 25, 2009. On August 28, 2009, FACT announced that it signed a $186.5 million in-licensing deal with Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) for TRU-016, a phase I drug for chronic lymphocytic leukemia (CLL). BIIB said the agreement reduces the value of FACT and noted that FACT’s share prices fell substantially after the announcement of the collaboration.”
To read the entire report visit: http://www.investorsoup.com/lp/FACT
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.
Contact Information:
Investor Soup
Jeffrey Brown
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Investor Soup
Jeffrey Brown
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |